SOC	Without pertuzumab (n = 20,025)	With pertuzumab (n = 8,559)	ROR (95% CI)
Blood and lymphatic system disorders	1,864	1,151	1.51 (1.40 – 1.64)
Cardiac disorders	2,164	686	0.72 (0.66 – 0.79)
Congenital, familial and genetic disorders	4	3	1.75 (0.39 – 7.84)
Ear and labyrinth disorders	131	45	0.80 (0.57 – 1.13)
Endocrine disorders	51	24	1.10 (0.68 – 1.79)
Eye disorders	372	199	1.26 (1.06 – 1.50)
Gastrointestinal disorders	3,367	2,187	1.70 (1.60 – 1.81)
General disorders and administration site conditions	5,757	2,393	0.96 (0.91 – 1.02)
Hepatobiliary disorders	347	137	0.92 (0.76 – 1.13)
Immune system disorders	575	288	1.18 (1.02 – 1.36)
Infections and infestations	1,357	992	1.80 (1.65 – 1.97)
Injury, poisoning and procedural complications	970	716	1.79 (1.62 – 1.98)
Investigations	2,288	1,098	1.14 (1.06 – 1.23)
Metabolism and nutrition disorders	742	499	1.61 (1.43 – 1.81)
Musculoskeletal and connective tissue disorders	2,018	760	0.87 (0.80 – 0.95)
Neoplasms benign, malignant and unspecified (including cysts and polyps)	920	423	1.08 (0.96 – 1.21)
Nervous system disorders	2,609	1,284	1.18 (1.10 – 1.27)
Pregnancy, puerperium and perinatal conditions	52	11	0.49 (0.26 – 0.95)
Psychiatric disorders	1,687	449	0.60 (0.54 – 0.67)
Renal and urinary disorders	309	170	1.29 (1.07 – 1.56)
Reproductive system and breast disorders	133	103	1.82 (1.41 – 2.36)
Respiratory, thoracic and mediastinal disorders	2,448	1,102	1.06 (0.98 – 1.14)
Skin and subcutaneous tissue disorders	4,933	2,001	0.93 (0.88 – 0.99)
Social circumstances	379	59	0.36 (0.27 – 0.47)
Surgical and medical procedures	114	38	0.78 (0.54 – 1.13)
Vascular disorders	1,183	485	0.96 (0.86 – 1.07)
Product issues	27	15	1.30 (0.69 – 2.45)